Business and Liquidity Uncertainties (Tables)
|
9 Months Ended |
Sep. 30, 2021 |
|---|
| Business And Liquidity Uncertainties |
|
| Summary of Components of Marketable Securities |
Summary of Components of Marketable Securities
| |
|
As of September 30, 2021 |
|
| |
|
Amortized |
|
|
Unrealized |
|
|
Fair |
|
| |
|
Cost |
|
|
Losses |
|
|
Value |
|
| U.S. government obligations |
|
$ |
324 |
|
|
$ |
(1 |
) |
|
$ |
323 |
|
| Corporate obligations |
|
|
13,912 |
|
|
|
(121 |
) |
|
|
13,791 |
|
| |
|
$ |
14,236 |
|
|
$ |
(122 |
) |
|
$ |
14,114 |
|
| |
|
As of December 31, 2020 |
|
| |
|
Amortized |
|
|
Unrealized |
|
|
Fair |
|
| |
|
Cost |
|
|
Losses |
|
|
Value |
|
| U.S. government obligations |
|
$ |
1,021 |
|
|
$ |
(7 |
) |
|
$ |
1,014 |
|
| Corporate obligations |
|
|
629 |
|
|
|
(4 |
) |
|
|
625 |
|
| |
|
$ |
1,650 |
|
|
$ |
(11 |
) |
|
$ |
1,639 |
|
|
| Schedule of Components of Inventory |
Schedule of Components of Inventory
| |
|
September 30, |
|
|
December 31, |
|
| |
|
2021 |
|
|
2020 |
|
| Diagnostic services testing material |
|
$ |
6,203 |
|
|
$ |
1,028 |
|
| Raw materials |
|
|
1,464 |
|
|
|
1,404 |
|
| Work in process |
|
|
407 |
|
|
|
437 |
|
| Finished goods |
|
|
436 |
|
|
|
170 |
|
| Inventory, net |
|
$ |
8,510 |
|
|
$ |
3,039 |
|
|
| Schedule of Fair Value of Financial Instruments |
Schedule of Fair Value of Financial Instruments
| |
|
As of September 30, 2021 |
|
| |
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
| Marketable debt securities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| U.S. government obligations |
|
$ |
- |
|
|
$ |
323 |
|
|
$ |
- |
|
|
$ |
323 |
|
| Corporate obligations |
|
|
- |
|
|
|
13,791 |
|
|
|
- |
|
|
|
13,791 |
|
| Marketable equity securities |
|
|
214 |
|
|
|
- |
|
|
|
- |
|
|
|
214 |
|
| |
|
$ |
214 |
|
|
$ |
14,114 |
|
|
$ |
- |
|
|
$ |
14,328 |
|
| |
|
As of December 31, 2020 |
|
| |
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
| Marketable debt securities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| U.S. government obligations |
|
$ |
- |
|
|
$ |
1,014 |
|
|
$ |
- |
|
|
$ |
1,014 |
|
| Corporate obligations |
|
|
- |
|
|
|
625 |
|
|
|
- |
|
|
|
625 |
|
| |
|
$ |
- |
|
|
$ |
1,639 |
|
|
$ |
- |
|
|
$ |
1,639 |
|
|
| Schedule of Deferred Revenue |
The
following table disaggregates our deferred revenue by recognition period (in thousands):
Schedule of Deferred Revenue
| |
|
As of September 30, 2021 |
|
|
As of December 31, 2020 |
|
| Recognition Period |
|
|
|
|
|
|
|
|
| 0-12 Months |
|
$ |
1,517 |
|
|
$ |
169 |
|
| 13-24 Months |
|
|
71 |
|
|
|
84 |
|
| Over 24 Months |
|
|
35 |
|
|
|
78 |
|
| Total |
|
$ |
1,623 |
|
|
$ |
331 |
|
|
| Schedule of Disaggregation by Revenue |
The
following table disaggregates our revenue by revenue source for the three and nine months ended September 30, 2021 and 2020 (in thousands):
Schedule of Disaggregation by Revenue
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
For the three months ended |
|
|
For the nine months ended |
|
| Revenue by Customer Type |
|
September 30, 2021 |
|
|
September 30, 2020 |
|
|
September 30, 2021 |
|
|
September 30, 2020 |
|
| Contract manufacturing |
|
$ |
1,120 |
|
|
$ |
3,630 |
|
|
$ |
4,069 |
|
|
$ |
8,825 |
|
| Retail and others |
|
|
1,210 |
|
|
|
210 |
|
|
|
2,400 |
|
|
|
526 |
|
| Diagnostic services |
|
|
7,142 |
|
|
|
- |
|
|
|
27,416 |
|
|
|
- |
|
| Total revenue, net |
|
$ |
9,472 |
|
|
$ |
3,840 |
|
|
$ |
33,885 |
|
|
$ |
9,351 |
|
|